Preparing Your Action Plan for the FDA sIRB Mandate
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Conducting Research With CAR T Cells Regulatory and Practical Considerations Having proven successful in trials for blood cancers considered resistant
Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their
CAR T Manufacturing and Toxicity Pre-Clinical Considerations Genetically engineered therapeutics present diverse, and sometimes heightened, risks compared to traditional small
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While
Explore the state of DE&I in clinical research with survey insights on diversity plans, budgeting efforts, and progress in trial representation.
Discover how Parexel accelerated mRNA study startups with Advarra’s integrated IRB and IBC reviews, achieving rapid timelines and budget goals.
Ensuring the safe and secure transport of investigational products (IP) is a core part of biosafety. This critical task requires
The clinical trial startup process has seen significant shifts over the past five years: growth in decentralized trials, improved technology,
The clinical research industry is only becoming more complex and competitive as organizations are inundated with multiple trials and tight